Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 11;25(22):12081.
doi: 10.3390/ijms252212081.

Adeno-Associated Viral Vectors in the Treatment of Epilepsy

Aysilu I Mullagulova  1 , Elena E Timechko  2 , Valeriya V Solovyeva  1 , Alexey M Yakimov  2 , Ahmad Ibrahim  1 , Diana D Dmitrenko  2 , Albert A Sufianov  3   4 , Galina Z Sufianova  5 , Albert A Rizvanov  1   6
Affiliations
Review

Adeno-Associated Viral Vectors in the Treatment of Epilepsy

Aysilu I Mullagulova et al. Int J Mol Sci. .

Abstract

Epilepsy is a brain disorder characterized by a persistent predisposition to epileptic seizures. With various etiologies of epilepsy, a significant proportion of patients develop pharmacoresistance to antiepileptic drugs, which necessitates the search for new therapeutic methods, in particular, using gene therapy. This review discusses the use of adeno-associated viral (AAV) vectors in gene therapy for epilepsy, emphasizing their advantages, such as high efficiency of neuronal tissue transduction and low immunogenicity/cytotoxicity. AAV vectors provide the possibility of personalized therapy due to the diversity of serotypes and genomic constructs, which allows for increasing the specificity and effectiveness of treatment. Promising orientations include the modulation of the expression of neuropeptides, ion channels, transcription, and neurotrophic factors, as well as the use of antisense oligonucleotides to regulate seizure activity, which can reduce the severity of epileptic disorders. This review summarizes the current advances in the use of AAV vectors for the treatment of epilepsy of various etiologies, demonstrating the significant potential of AAV vectors for the development of personalized and more effective approaches to reducing seizure activity and improving patient prognosis.

Keywords: adeno-associated virus; antisense oligonucleotides; epilepsy; gene therapy; ion channels; neuropeptides; neurotrophic factors; receptors; transcription factors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Components of the effective use of AAV vectors in the treatment of CNS disorders.
Figure 2
Figure 2
Experimental design for evaluating the efficacy of AAV vectors (serotypes 1, 2 and 8) carrying neuropeptide Y (NPY) and its receptor Y2 in two different transgene orders (NPY/Y2 or Y2/NPY); empty viral cassettes were used as a control. Wistar male rats were injected bilaterally with the viral vectors, followed by subcutaneous kainate injection to induce seizures. Key measurements included latency to the first motor seizure, time spent in motor seizure and latency to status epilepticus. Results from these measurements were used to assess the seizure-suppressant efficacy of the AAV vectors compared to an empty cassette control vector.
See this image and copyright information in PMC

References

    1. Fisher R.S., Acevedo C., Arzimanoglou A., Bogacz A., Cross J.H., Elger C.E., Engel J., Jr., Forsgren L., French J.A., Glynn M., et al. ILAE official report: A practical clinical definition of epilepsy. Epilepsia. 2014;55:475–482. doi: 10.1111/epi.12550. - DOI - PubMed
    1. Riney K., Bogacz A., Somerville E., Hirsch E., Nabbout R., Scheffer I.E., Zuberi S.M., Alsaadi T., Jain S., French J., et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age: Position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022;63:1443–1474. doi: 10.1111/epi.17240. - DOI - PubMed
    1. Scheffer I.E., Berkovic S., Capovilla G., Connolly M.B., French J., Guilhoto L., Hirsch E., Jain S., Mathern G.W., Moshé S.L., et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:512–521. doi: 10.1111/epi.13709. - DOI - PMC - PubMed
    1. Fisher R.S., Cross J.H., French J.A., Higurashi N., Hirsch E., Jansen F.E., Lagae L., Moshé S.L., Peltola J., Roulet Perez E., et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:522–530. doi: 10.1111/epi.13670. - DOI - PubMed
    1. Dos Santos R.R., Bernardino T.C., da Silva M.C.M., de Oliveira A.C.P., Drumond L.E., Rosa D.V., Massensini A.R., Moraes M.F.D., Doretto M.C., Romano-Silva M.A., et al. Neurochemical abnormalities in the hippocampus of male rats displaying audiogenic seizures, a genetic model of epilepsy. Neurosci. Lett. 2021;761:136123. doi: 10.1016/j.neulet.2021.136123. - DOI - PubMed